TG Therapeutics to Host Conference Call on Second Quarter 2021 Financial Results and Business Update
July 28 2021 - 7:30AM
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a
conference call will be held on Monday, August 2, 2021 at 8:30 AM
ET to discuss results for the second quarter 2021 and provide a
business outlook for the remainder of the year. Michael S. Weiss,
Chairman and Chief Executive Officer, will host the call.
In order to participate in the conference call, please call
1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.),
Conference Title: TG Therapeutics. A live webcast of this
presentation will be available on the Events page, located within
the Investors & Media section, of the Company's website at
www.tgtherapeutics.com. An audio recording of the conference call
will also be available for a period of 30 days after the call.
TG Therapeutics will announce its financial results for this
period in a press release to be issued prior to the call.
ABOUT TG THERAPEUTICS, INC.TG
Therapeutics is a fully-integrated, commercial stage
biopharmaceutical company focused on the acquisition, development
and commercialization of novel treatments for B-cell malignancies
and autoimmune diseases. In addition to an active research pipeline
including five investigational medicines across these therapeutic
areas, TG has received accelerated approval from
the U.S. FDA for UKONIQ® (umbralisib), for the
treatment of adult patients with relapsed/refractory marginal zone
lymphoma who have received at least one prior anti-CD20-based
regimen and relapsed/refractory follicular lymphoma who have
received at least three prior lines of systemic therapies.
Currently, the Company has three programs in Phase 3 development
for the treatment of patients with relapsing forms of multiple
sclerosis (RMS) and patients with chronic lymphocytic leukemia
(CLL) and several investigational medicines in Phase 1 clinical
development. For more information,
visit www.tgtherapeutics.com, and follow us on
Twitter @TGTherapeutics and Linkedin.
UKONIQ® is a trademark of TG Therapeutics, Inc.
CONTACT:
Investor Relations Email:
ir@tgtxinc.comTelephone: 1.877.575.TGTX (8489), Option 4
Media Relations: Email:
media@tgtxinc.comTelephone: 1.877.575.TGTX (8489), Option 6
TG Therapeutics (NASDAQ:TGTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
TG Therapeutics (NASDAQ:TGTX)
Historical Stock Chart
From Sep 2023 to Sep 2024